Prostate-Specific Antigen Test Market Analysis

Prostate-Specific Antigen Test Market Analysis

To get key market trends

  Download Free Sample

The market by test type is categorized into preliminary tests and confirmatory tests. The preliminary tests segment is further segmented into total prostate specific antigen test, complex prostate specific antigen test, and free prostate specific antigen test. The confirmatory tests segment is further divided into PCA3 test, trans-rectal ultrasound, and biopsy. The preliminary tests segment was valued at USD 2.7 billion revenue in the year 2022.
 

• Advancements in genetic testing and biomarker testing have enabled the detection of specific indicators associated with a higher risk of prostate cancer. These tests can be valuable in assessing the need for preliminary testing.
   
• Furthermore, early detection of prostate cancer can lead to improved treatment outcomes. Preliminary tests play a vital role in identifying individuals at a higher risk, prompting the need for screening to detect cancer at an early and treatable stage.
   

Based on application, the prostate-specific antigen test market is segmented into prostate cancer screening and prostate cancer monitoring. The prostate cancer screening segment dominated the market and accounted for over 54.3% business share in the year 2022 and is anticipated to witness significant growth during the forecast period.
 

• Prostate cancer predominantly affects older men, and the global aging population serves as a major catalyst for screening. With advancing age, the risk of developing prostate cancer rises, resulting in a heightened demand for screening among the elderly.
   
• In addition, the establishment of standardized protocols for prostate cancer screening is shaped by clinical guidelines and recommendations provided by medical organizations. These guidelines actively encourage collaborative decision-making between patients and healthcare providers, ultimately enhancing the efficacy and accessibility of screening processes.
   

The prostate-specific antigen test market by end-use is categorized into hospitals, specialty clinics, diagnostic centers, and other end-use. The hospitals segment was valued at USD 1.5 billion revenue size in the year 2022.
 

• The hospital segment is witnessing growth primarily due to a surge in patient awareness regarding the importance of regular prostate cancer screening. As the hospitals are well-equipped with advanced diagnostic equipment and experienced medical professionals. This makes them ideal facilities for conducting PSA tests accurately and providing comprehensive care for patients who require further evaluation or treatment.
   
• Moreover, hospitals are quick to embrace cutting-edge diagnostic technologies, including multiparametric magnetic resonance imaging (mpMRI) and other imaging methods. These advanced tools can complement PSA testing, leading to enhanced precision and diagnostic accuracy. As a result, this is expected to drive growth within this market segment.
   

North America prostate-specific antigen test market accounted for USD 1.5 billion revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.
 

• North America has emerged as a dynamic and burgeoning hub in the global prostate-specific antigen (PSA) testing market. This growth can be attributed to a combination of demographic shifts, increased awareness, and technological advancements within the region. A substantial proportion of men in this region fall into the 50 and older age group, and prostate cancer risk escalates with age. This demographic trend has consequently led to a rising demand for PSA testing. As a result, the region is expected to maintain its upward trajectory as awareness and technology continue to advance.
   
• Furthermore, North America has a well-developed healthcare infrastructure, with numerous hospitals, clinics, and diagnostic centers equipped to provide PSA testing services. Access to healthcare facilities is a significant driver, contributing to the market's progress.